All News

Tildrakizumab, IL-23 mAb) was well tolerated in ankylosing spondylitis (AS) pts but did improve ASAS20 responses vs PBO. 101 pts given TIL or PBO. ASAS20 response was 74% TIL vs 80% PBO. Study was terminated at week 24 for lack of efficacy. https://t.co/1PdyDbAILs https://t.co/44O23ZVvrc

Links:

Dr. John Cush RheumNow ( View Tweet)
Aug 20, 2023
Tildrakizumab, IL-23 mAb) was well tolerated in ankylosing spondylitis (AS) pts but did improve ASAS20 responses vs PBO. 101 pts given TIL or PBO. ASAS20 response was 74% TIL vs 80% PBO. Study was terminated at week 24 for lack of efficacy. https://t.co/gje5hGAyOV https://t.co/gtMBpcQdGq

Links:

Dr. John Cush RheumNow ( View Tweet)
Aug 17, 2023
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

d Jack Cush, MD
Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
IL-23 Inhibitor Performance in Psoriatic Disease A single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA. https://t.co/J3HIDBguj1 https://t.co/uqYf0Bdh0n

Links:

Dr. John Cush RheumNow ( View Tweet)
Jul 31, 2023
pso.PsA_.NPF_.jpg

IL-23 Inhibitor Performance in Psoriatic Disease

d Jack Cush, MD
Jul 27, 2023

IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.

Read Article
Double blind RCT of 101 active AS patients with BASDAI ≥4 showed the IL-23 inhibitor, tildrakizumab was not superior to placebo after 24 weeks (ASAS20: 74% on tildrakizumab 200 mg vs 80% on PBO). Study was terminated after wk 24 interim analysis https://t.co/zZxiAk6A5o https://t.co/P1tNX8BN6C

Links:

Dr. John Cush RheumNow ( View Tweet)
Jul 25, 2023
Rheumatoid,RA,nodules,damage

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

d Jack Cush, MD
May 25, 2023

Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).

Read Article
PSA068.jpg

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

d Jack Cush, MD
May 12, 2023

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.

Read Article
Lillys IL-23 inhibitor (Mirakizumab) has suffered a minor setback receiving a "complete response letter" from the FDA regarding MIRA application (BLA) for use in ulcerative colitis. The CRL hold up is related to the manufacturing issues (not data/safety) https://t.co/Xs93pFNFAp https://t.co/vlVP8qiqGr

Links:

Dr. John Cush RheumNow ( View Tweet)
Apr 17, 2023
RheumNow Podcast square

Night Splinting for Carpal Tunnel (3.24.2023)

d Jack Cush, MD
Mar 24, 2023

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Read Article
Open-label trial of Guselkumab (IL-23 inhib) in 20 moderate-to-severe hidradenitis suppurativa (HS) pts saw 65% with HiSCR response at wk 16. Yet phase IIB NOVA PBO-RCT showed GUS HiSCR response 45–51% (vs 39% PBO). GUS may only benefit subgroup of HS https://t.co/OxtFfyRMFk https://t.co/hnQyU0VWxg

Links:

Dr. John Cush RheumNow ( View Tweet)
Mar 16, 2023
Does Biologic Treatment in Psoriasis Reduce the Risk of PsA? Retrospective claims analysis shows that psoriasis patients treated with an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident PsA. https://t.co/j73V7zMnkn https://t.co/EhGUXDNNlS

Links:

Dr. John Cush RheumNow ( View Tweet)
Mar 09, 2023
pso.PsA_.NPF_.jpg

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

d Jack Cush, MD
Mar 07, 2023

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article
RheumNow Podcast square

NSAIDs in Pregnancy (3.3.2023)

d Jack Cush, MD
Mar 03, 2023

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Read Article
colitis.jpg

VEGA - The Efficacy of Combination Biologics in Ulcerative Colitis

d Jack Cush, MD
Mar 02, 2023

A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.

Read Article
PSA2L.jpg

Psoriatic Arthritis: Depressing News on Second- and Later-Line Treatments

d MedPage Today
Feb 28, 2023

Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.

Read Article
Subanalysis of DISCOVER-1 RCT w/ IL-23 inhibitor guselkumab, showed similar response in TNFi-naive (n 118) & TNFi-experienced (263) Rx w/ guselkumab Q4W (76% & 68%) or Q8W (61% & 58%), yet skin responses (PASI90) were better in TNFi-naive Rx PsA pts. https://t.co/tsKuLZw7dQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Feb 14, 2023
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx

Links:

Dr. John Cush RheumNow ( View Tweet)
Jan 25, 2023
173 PsA pts enrolled to start ustekinumab: half on MTX and half on PBO. At week 24 there was no difference in DAS28 between groups (2.9 vs 3.1); then Ustekinumab plus placebo was non-inferior to ustekinumab plus methotrexate https://t.co/AygtawIZsZ https://t.co/YLGp5lMWT9

Links:

Dr. John Cush RheumNow ( View Tweet)
Jan 16, 2023
PsABiostudy followed PsA pts starting TNFi vs ustekinumab x12 mos showing equivalent durability at 1 yr (72% vs 71%). cDAPSA LDA was seen in 56% UST vs 67% TNFi (similar for MDA (34% vs 43%) https://t.co/briK7itZtL https://t.co/Rq1SXA7s1s

Links:

Dr. John Cush RheumNow ( View Tweet)
Jan 10, 2023

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×